Prolastin Related Published Studies
Well-designed clinical trials related to Prolastin (Alpha 1-Antitrypsin)
Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma--results from the ALA-ACRC low-dose theophylline trial. [2007.10]
Alpha-1-antitrypsin replacement therapy: current status. [2006.03]
Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. [2006.03]
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. [2006.02]
Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency. [2005.05.31]
Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome? [2005]
Prevalence of alpha1-antitrypsin phenotypes in patients with IgA nephropathy. [2004.12]
Protease inhibitors alpha1-antitrypsin and ilomastat are not ototoxic in the chinchilla. [2003.10]
Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. [2003.08]
Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. [2002.07]
Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. [2001.03]
Alpha-1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. [2001]
Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. [2000.03]
A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. [1999.11]
Functional and antigenic concentrations of alpha-1-proteinase inhibitor after administration for the prevention of chronic lung disease of prematurity. [1999.09]
alpha1-Proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial. [1998.01]
Progress of emphysema in severe alpha 1-antitrypsin deficiency as assessed by annual CT. [1997.09]
Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase-alpha 1-proteinase inhibitor in gingival crevicular fluid. [1996.03]
Effects of low dose methotrexate therapy on the concentration and the glycosylation of alpha 1-acid glycoprotein in the serum of patients with rheumatoid arthritis: a longitudinal study. [1994.12]
Well-designed clinical trials possibly related to Prolastin (Alpha 1-Antitrypsin)
The benefit of daily photoprotection. [2008.05]
No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. [2006.07]
Rectal bleeding in infancy: clinical, allergological, and microbiological examination. [2006.04]
Effects of ulinastatin on pulmonary artery pressure during abdominal aortic aneurysmectomy. [2006.02]
Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. [2005.02]
Residues 34-39 in the thyrotropin receptor are not the target of autoantibodies from sera of patients with Graves' disease. [2004.08]
Tissue trauma after vaginal hysterectomy and colporrhaphy versus abdominal hysterectomy: a randomised controlled study. [2004.08]
Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. [2004.03]
Effect of early enteral nutrition on intestinal permeability, intestinal protein loss, and outcome in dogs with severe parvoviral enteritis. [2003.11]
The value of routine antibiotic prophylaxis in mandibular third molar surgery: acute-phase protein levels as indicators of infection. [2001.06]
Tension-free hernia repair is associated with an increase in inflammatory response markers against the mesh. [2000.09]
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. [2000.07]
Treatment of iron deficiency anemia and associated protein-losing enteropathy in children. [2000.01]
Activation of the contact system of coagulation does not contribute to the hemostatic imbalance in hypertriglyceridemia. [1999.10]
Reducing neutrophil elastase-induced lung injury. [1999.03]
Inhaled budesonide in ventilator-dependent preterm infants: a randomized, double-blind pilot study. [1999]
Activation of the protein C system during cardiopulmonary bypass with and without aprotinin. [1998.12]
Peritoneal lavage with aprotinin in patients with severe acute pancreatitis. Effects on plasma and peritoneal levels of trypsin and leukocyte proteases and their major inhibitors. [1998.08]
Steroids in the hemolytic uremic syndrome. [1998.02]
Probiotics: a novel approach in the management of food allergy. [1997.02]
Ozone exposure has both a priming effect on allergen-induced responses and an intrinsic inflammatory action in the nasal airways of perennially allergic asthmatics. [1995.05]
Local serum application: restoration of sufficient host defense in human peritonitis. [1994.01]
Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. [1994.01]
Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. [1993.06]
The effect of bed rest and intra-articular steroids on the acute phase response in rheumatoid arthritis. [1993.01]
The effect of epidural blockade on postoperative hypercoagulability following abdominal aortic bypass surgery. [1992.11]
The influence of tourniquet ischaemia on post-operative degranulation of polymorphonuclear granulocytes. [1992.05]
Attenuation of intra-operative surgical stress response has no influence on post-operative degranulation of polymorphonuclear granulocytes. [1991.09]
Effect of dexamethasone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia. [1991.05]
Comparison of the clinical performance, contraceptive efficacy and acceptability of levonorgestrel-releasing IUD and Norplant-2 implants in China. [1990.05]
Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration. [1988.02]
Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. [1987.10]
Other research related to Prolastin (Alpha 1-Antitrypsin)
Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro. [2008.07]
[Effect of a high glucose load on serum concentrations of C-reactive protein and alpha1-antitrypsin in obese women] [2008.07]
Endothelial alpha-1-antitrypsin attenuates cigarette smoke induced apoptosis in vitro. [2008.06]
Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ alpha1-antitrypsin phenotype. [2008.05]
Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy. [2008.05]
Alpha-1 antitrypsin: now available, but do we need it? [2008.04.05]
Augmentation therapy in alpha-1 antitrypsin deficiency. [2008.04]
Inhaled Corticosteroids as Additional Treatment in Alpha-1-Antitrypsin-Deficiency-Related COPD. [2008.03.04]
Alpha-1 antitrypsin treatment of spontaneously diabetic nonobese diabetic mice receiving islet allografts. [2008.03]
Prolonged islet allograft survival by alpha-1 antitrypsin: the role of humoral immunity. [2008.03]
Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; methodological advances. [2008.02.13]
Longitudinal Decline of Diffusing Capacity of the Lung for Carbon Monoxide (DL,CO) in Community Subjects with the PiMZ {alpha}1-Antitrypsin Phenotype. [2008.02.08]
Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. [2008.01]
IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency. [2008.01]
Influenza vaccination in subjects with alpha1-antitrypsin deficiency. [2008.01]
Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD. [2008]
The prevalence of alpha(1)-antitrypsin deficiency in a representative population sample from Poland. [2007.12]
Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency. [2007.10]
The promise of gene therapy for the treatment of alpha-1 antitrypsin deficiency. [2007.09]
Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency. [2007.09]
Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. [2007.09]
The prevalence of alpha(1)-antitrypsin deficiency in a representative population sample from Poland. [2007.08.09]
Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages. [2007.08]
Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program. [2007.08]
Fecal alpha1--antitrypsin in healthy and intestinal-disorder Thai children. [2007.07]
Alpha1-antitrypsin heterozygosity plays a positive role in attainment of longevity. [2007.04]
Rapid and Inexpensive Detection of {alpha}1-Antitrypsin Deficiency-Related Alleles S and Z by a Real-Time Polymerase Chain Reaction Suitable for a Large-Scale Population-Based Screening. [2007.02]
{alpha}1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. [2007.02]
Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. [2007.02]
Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. [2007.01]
Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. [2006.12]
Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. [2006.12]
Identification of a 4-mer Peptide Inhibitor that Effectively Blocks the Polymerization of Pathogenic Z {alpha}1-Antitrypsin. [2006.11]
Yield improvement for manufacture of alpha-proteinase inhibitor. [2006.11]
Alpha-1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. [2006.10.18]
Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. [2006.10]
[Pharmacokinetics of alpha1-antitrypsin replacement therapy in severe congenital emphysema] [2006.10]
Deficient alpha-1-antitrypsin phenotypes and persistent airflow limitation in severe asthma. [2006.09]
Prolastin aerosol therapy and sputum taurine in cystic fibrosis. [2006.08]
Ventilation inhomogeneity in alpha1-antitrypsin-deficient emphysema. [2006.08]
Alpha1-antitrypsin single dose adjuvant therapy for acute otitis media. [2006.07]
A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. [2006.06.01]
Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. [2006.06]
Inhaled recombinant alpha 1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. [2006.06]
Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. [2006.06]
High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. [2006.01]
Quantitative assessment of emphysema distribution in smokers and patients with alpha1-antitrypsin deficiency. [2006.01]
Results of a survey of patients with alpha-1 antitrypsin deficiency. [2006]
Tempting liver fibrosis? Long-term psoriatic methotrexate therapy and heterozygous alpha1-antitrypsin deficiency. [2006]
[National cohort of patients with emphysema and alpha-1 antitrypsin deficiency] [2005.12]
|
